肿瘤细胞治疗研究
英文原题：γδ T cells in immunotherapies for B-cell malignancies.
尽管B细胞恶性肿瘤的治疗取得了进展，患者的长期生存率有所提高，但其中近一半的患者仍会复发。
尽管B细胞恶性肿瘤的治疗取得了进展，患者的长期生存率有所提高，但几乎一半的患者仍会复发。化疗与抗CD20等单克隆抗体的联合治疗结果不一。近年来基于免疫细胞的疗法展现出许多令人鼓舞的结果。γδ T细胞因其功能可塑性的潜力及抗肿瘤特性，成为癌症免疫治疗的良好候选者。γδ T细胞在组织与血液中、在生理条件下或在B细胞恶性肿瘤如B细胞淋巴瘤、慢性淋巴细胞白血病或多发性骨髓瘤中的代表性和多样性，为通过免疫治疗方法对这些患者进行调控提供了可能。在本综述中，我们总结了几种基于γδ T细胞激活和肿瘤靶向的策略、扩增方案的优化，以及基因修饰γδ T细胞的开发，利用抗体与治疗药物的联合，以及在潜在基因修饰后采用自体或异体γδ T细胞的过继细胞疗法。
Despite the advancements in therapy for B cell malignancies and the increase in long-term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results. γδ T cells, with their potential of functional plasticity and their anti-tumoral properties, emerged as good candidates for cancer immunotherapies. The representation and the diversity of γδ T cells in tissues and in the blood, in physiological conditions or in B-cell malignancies such as B cell lymphoma, chronic lymphoblastic leukemia or multiple myeloma, provides the possibility to manipulate them with immunotherapeutic approaches for these patients. In this review, we summarized several strategies based on the activation and tumor-targeting of γδ T cells, optimization of expansion protocols, and development of gene-modified γδ T cells, using combinations of antibodies and therapeutic drugs and adoptive cell therapy with autologous or allogenic γδ T cells following potential genetic modifications.
MEMBER ACCOUNT
登录成功会直接打开下一页。
